Literature DB >> 11756646

Growth, IGF system, and cortisol in children with intrauterine growth retardation: is catch-up growth affected by reprogramming of the hypothalamic-pituitary-adrenal axis?

Stefano Cianfarani1, Caterina Geremia, Carolyn D Scott, Daniela Germani.   

Abstract

Intrauterine growth retardation (IUGR) is one of the major causes of short stature in childhood. Although postnatal catch-up growth occurs in the majority of IUGR children, approximately 20% of them remain permanently short. The mechanisms that allow catch-up growth or, on the contrary, prevent IUGR children from achieving a normal height are still unknown. Our aim was to investigate whether intrauterine reprogramming of hypothalamic-pituitary-adrenal axis may be involved in postnatal growth retardation of IUGR children through a modulation of the function of the IGF system. Anthropometry, IGF system assessment, cortisol measurement, and lipid profile evaluation were performed in 49 IUGR children. Children were subdivided into two groups according to their actual height corrected for midparental height: CG (catch-up growth) group, 19 children with corrected height >or=0 z-score; and NCG (noncatch-up growth) group, 30 subjects with corrected height <0 z-score. CG children showed significantly higher birth weight (p < 0.005) and body mass index (p < 0.05). No significant differences in IGF-I, IGF-II, IGF binding protein (IGFBP)-1, IGFBP-3, soluble IGF-II receptor levels (IGF2R), IGF-II/IGF2R ratio, and relative amounts of IGFBP-3 circulating forms were found between CG and NCG children. None of the IGF system-related variables correlated with anthropometric indices. NCG children showed significantly higher concentrations of cortisol (p < 0.005) and cortisol levels resulted inversely to birth weigh (r = -0.34, p < 0.05), birth length (r = -0.36, p < 0.05), and corrected height (r = -0.44, p < 0.01). Whereas total and HDL cholesterol concentrations were not significantly different in the two groups, LDL cholesterol levels were significantly higher in NCG children (p < 0.05), and five of 49 showed LDL cholesterol concentrations >3.4 mM (130 mg/dL). LDL cholesterol was inversely related to birth weight (r = -0.31, p < 0.05), corrected stature (r = -0.32, p < 0.05), and actual height (r = -0.31, p < 0.05) and directly related to the levels of IGF2R (r = 0.44, p < 0.01). Reanalysis of 15 of 30 IUGR newborns in whom we previously reported an inverse relationship between cord blood cortisol levels and first trimester length gain (r = -0.54, p < 0.005) showed that the relative amount of the IGFBP-3 18-kD fragment was related inversely to cortisol (r = -0.67, p < 0.01) and directly to early postnatal growth (r = 0.65, p < 0.05). Our results suggest that catch-up growth in IUGR children might be affected by intrauterine reprogramming of hypothalamic-pituitary-adrenal axis, which may result in a permanent modification of the neuroendocrine response to stress: children with increased cortisol secretion may be at higher risk of growth failure. During the neonatal period cortisol might act by limiting IGFBP-3 proteolysis and, therefore, reducing IGF bioavailability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11756646     DOI: 10.1203/00006450-200201000-00017

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

1.  Effects of dietary methionine restriction on postnatal growth, insulin sensitivity, and glucose metabolism in intrauterine growth retardation pigs at 49 and 105 d of age.

Authors:  Zhixiong Ying; Xiaoke Ge; Hao Zhang; Weipeng Su; Yue Li; Le Zhou; Lili Zhang; Tian Wang
Journal:  J Anim Sci       Date:  2019-02-01       Impact factor: 3.159

2.  Catch-up growth in body mass index is associated neither with reduced insulin sensitivity nor with altered lipid profile in children born small for gestational age.

Authors:  P Torre; C Ladaki; G Scirè; G L Spadoni; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

3.  Insulin sensitivity in children born small for gestational age (SGA).

Authors:  Caterina Geremia; Stefano Cianfarani
Journal:  Rev Diabet Stud       Date:  2004-08-10

Review 4.  Should recombinant human growth hormone therapy be used in short small for gestational age children?

Authors:  L B Johnston; M O Savage
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

5.  Early deprivation and home basal cortisol levels: a study of internationally adopted children.

Authors:  Darlene A Kertes; Megan R Gunnar; Nicole J Madsen; Jeffrey D Long
Journal:  Dev Psychopathol       Date:  2008

Review 6.  Growth and body composition in very young SGA children.

Authors:  Jesús Argente; Otto Mehls; Vicente Barrios
Journal:  Pediatr Nephrol       Date:  2010-01-27       Impact factor: 3.714

7.  Dyslipidaemia and undernutrition in children from impoverished areas of Maceió, state of Alagoas, Brazil.

Authors:  Gabriela R S Veiga; Haroldo S Ferreira; Ana L Sawaya; Jairo Calado; Telma M M T Florêncio
Journal:  Int J Environ Res Public Health       Date:  2010-11-30       Impact factor: 3.390

8.  Effects of cord serum insulin, IGF-II, IGFBP-2, IL-6 and cortisol concentrations on human birth weight and length: pilot study.

Authors:  Arianna Smerieri; Maddalena Petraroli; Maria Angela Ziveri; Cecilia Volta; Sergio Bernasconi; Maria E Street
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

9.  Liver transcriptome profiling and functional analysis of intrauterine growth restriction (IUGR) piglets reveals a genetic correction and sexual-dimorphic gene expression during postnatal development.

Authors:  Hongmei Gao; Longchao Zhang; Ligang Wang; Xin Liu; Xinhua Hou; Fuping Zhao; Hua Yan; Lixian Wang
Journal:  BMC Genomics       Date:  2020-10-08       Impact factor: 3.969

10.  Effect of Dydrogesterone on the Outcome of Idiopathic Intrauterine Growth Restriction: A Double-blind Clinical Trial Study.

Authors:  Elaheh Zarean; Fatemeh Mostajeran; Zahra Dayani
Journal:  Adv Biomed Res       Date:  2018-06-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.